The trading price of Matinas Biopharma Holdings Inc (AMEX:MTNB) closed higher on Monday, July 15, closing at $0.18, 7.54% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $0.89 and a 52-week low of $0.11. Over the past month, the stock has gained 17.81% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Matinas Biopharma Holdings Inc, whose market valuation is $45.80 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest MTNB has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that MTNB’s price is currently 13.78% off the SMA20 and 10.89% off the SMA50. The RSI metric on the 14-day chart is currently showing 65.55, and weekly volatility stands at 5.66%. When measured over the past 30 days, the indicator reaches 5.40%. Matinas Biopharma Holdings Inc (AMEX:MTNB)’s beta value is currently sitting at 1.70, while the Average True Range indicator is currently displaying 0.01.
To see how Matinas Biopharma Holdings Inc stock has been performing in comparison to its peers in the industry, here are the numbers: MTNB stock’s performance was 7.54% in the latest trading, and -50.99% in the past year.
An evaluation of the daily trading volume of Matinas Biopharma Holdings Inc (AMEX:MTNB) indicates that the 3-month average is 902.32K.
Currently, records show that 250.82 million of the company’s shares remain outstanding. The insiders hold 2.53% of outstanding shares, whereas institutions hold 11.09%. However, since the stock’s price has seen -15.54% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
